Merck KGaA, Darmstadt, Germany, Advances Immunology Pipeline with Evobrutinib (Bruton’s Tyrosine Kinase Inhibitor) September 12, 2017October 21, 2019 by / Share This.....LinkedinTwitterFacebookGoogleEmailDownload PDF Related News: Oxford Immunotec Debuts Global Immunology Services…Oncomine Dx Target Test Receives MHLW Approval as a…GE Healthcare Advances Precision Health &…Roche presents latest advances with immunotherapies…Roche presents new data at World Muscle Society…GE Healthcare Advances Precision Radiation Therapy…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
